El cáncer

Cáncer de mama, tumores génito urinarios, hematología oncológica, cáncer de vejiga, cáncer de riñón y cáncer de colon

Breast cancer
It is estimated that 1 in 8 women will develop breast cancer during their lifetime, with around 26,000 new cases diagnosed in Spain each year. Despite the increase in its incidence, mortality from this type of tumour is decreasing annually thanks to early diagnosis programmes and advances in its treatment.

The Cancer Unit at Centro Médico Teknon offers comprehensive, personalised care and boasts renowned specialists and state-of-the-art technology.
- Breast cancer treatment
  The treatment of breast cancer depends, among other variables, on the size and location of the tumour, and the extent or stage of the disease at the time of diagnosis. In most cases, the so-called trimodal therapy is usually performed: surgery, chemotherapy or hormone therapy, and radiotherapy. The usual sequence is to perform surgery first, followed by chemotherapy, should it become necessary, and radiotherapy. In some cases chemotherapy is given prior to surgery as an approach to large tumours to facilitate subsequent conservative surgery, or in cases with initial axillary lymph node involvement.
  
  Once the tumour has been removed, its pathological analysis (size, cell subtype, etc.) and biological characteristics (degree of malignancy, sensitivity or insensitivity to hormonal stimuli, etc.) determine the risk of local and/or distant recurrence and the need for post-surgical treatment to minimise this risk. The development of various genomic platforms over recent years has enabled the selection of patients for whom chemotherapy is essential, thereby avoiding its administration to patients for whom it is not necessary.
Genitourinary Tumours Unit
- Prostate cancer is one of the main health problems facing men. It is estimated that 3 out of 10 men over the age of 50 will develop prostate cancer during their lifetime. The most effective weapons to combat it are early detection through specific tests and multidisciplinary treatment at a centre of recognised excellence.
  
  Centro Médico Teknon has internationally renowned specialists who will help you prevent, diagnose and choose the most appropriate treatment in each case. These professionals will advise you and place special emphasis on resolving the major concerns arising from the disease:
  
  Removing the tumour and cancer cells
  
  Preserving maximum sexual potency
  
  Maintaining urinary continence
  
  Everything is done using the least invasive treatments that are offering the best results, as confirmed by medical studies:
  
  Laparoscopic surgery
  
  Da Vinci robot-assisted laparoscopic surgery
  
  Next-generation radiotherapy: True-Beam STX with the Calypso system
- Comprehensive solutions
  In the event of a positive diagnosis, you can rest assured that at Centro Médico Teknon you will receive the most appropriate treatment for your case.
  
  Radical prostatectomy with laparoscopy. The prostate gland and seminal vesicles are removed through small incisions using a minimally invasive technique, which minimises scarring, post-operative pain and hospital stay, and promotes faster recovery than traditional open surgery. This technique requires a high level of experience and expertise on the part of the specialist urologist performing it in order to achieve optimal results.
  
  Da Vinci robot-assisted radical prostatectomy. With its superior manoeuvrability, enhanced visual field and tremor-filtration, the Da Vinci robot ensures maximal precision in surgery, delivering all the advantages of minimally invasive surgery without the difficulties of conventional laparoscopic surgery. Research indicates that patients undergoing prostatectomy via the Da Vinci system experience faster restoration of urinary continence and sexual function, exhibit fewer positive margins, and face reduced risks compared to those having traditional open surgery or laparoscopy.
Haematology
The Haematology Oncology Unit at Centro Médico Teknon offers a comprehensive, personalised diagnosis for patients with lymphoproliferative diseases (lymphomas, leukaemias), as well as the most advanced and appropriate treatments for each case.

The Haematology Oncology Unit works closely with Teknon's Pathology Department and is supported by pathologists specialising in the diagnosis of lymphoproliferative diseases.

Thus, our Clinical Analysis Laboratory provides the Unit with the support required for blood diseases from a diagnostic point of view (cytology, flow cytometry, cytogenetics, and molecular biology).
Bladder Cancer
- ¿Cuál es la incidencia del cáncer de vejiga?
  El cáncer de vejiga es el segundo tumor más frecuente del sistema genitourinario después del cáncer de próstata. Su incidencia máxima se produce alrededor de la séptima década de vida.
- ¿Qué tipos de tumores existen y cuál es su tratamiento?
  La mayoría de los tumores de vejiga (75%) son tumores superficiales. Estos tumores se tratan fundamentalmente mediante resección transuretral (a través de la uretra mediante un citoscopio). En función del nivel de profundidad y del grado deberá realizarse tratamiento con quimioterapia o inmunoterapia locales
  
  El otro 25% son tumores infiltrantes. Estos tumores requieren un tratamiento más agresivo que consiste en la práctica de una cistectomía (extirpar la vejiga). En determinadas circunstancias precisarán de tratamiento con quimioterapia endovenosa y/o radioterapia.
Cáncer de riñon
El servicio de oncología es pionero en terapias antiangiogénicas y en inmunoterapia en cáncer de riñón metastásico. Igual que en el caso del cáncer de próstata, el enfoque multidisciplinar, con la participación de Urólogos, Radiooncólogos, Radiólogos y Patólogos es la norma en nuestro centro.

En los dos últimos años la inmunoterapia se ha incorporado como un tratamiento eficaz denle el carcinoma renal, desplazando en algunas situaciones a los antiangiogenicos.
Cáncer de colon
El cáncer colorrectal es el segundo cáncer con más incidencia en ambos sexos. En España cada año se diagnostican 9.000 nuevos casos de cáncer colorrectal y de estos, unos 2.200 son diagnosticados en Cataluña. La mayoría de cánceres de colon, un 65-85% son esporádicos, entre un 10-30% son de agregación familiar (cánceres que se acumulan en una familia por varias razones, como pueden ser compartir el mismo estilo de vida, exposiciones ambientales, etc.) y un 5-10% son de predisposición hereditaria.

Los factores de riesgo para desarrollar un cáncer de colon son:
- Edad: la mayoría de los cánceres de colon son diagnosticados después de los 50 años.
- Dieta y ejercicio: dietas ricas en grasa y poco ejercicio favorecen la aparición de cánceres colorrectales.
- Historia personal: una historia personal de pólipos incrementa el riesgo de cáncer de colon.
- Historia familiar o factores genéticos: las personas con familiares diagnosticados de cáncer colorrectal o familiares diagnosticados de Poliposis Adenomatosa Familiar (PAF) o de cáncer colorrectal hereditario no polipósico (CCHNP) tienen un riesgo elevado de desarrollar cáncer.

El cáncer

Subscriu-te a la nostra Newsletter